Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases including: leukaemia, lymphoma, multiple myeloma and X-linked retinitis pigmentosa.
The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.
Unless stated all financials at 30 September 2023
Value of late-stage clinical portfolio
Number of clinical trials
Portfolio company Board seats